<p>Orchestra BioMed Holdings, Inc.（納斯達克代碼：OBIO - 獲取免費報告）的股票在目前覆蓋該公司的六家評級機構中獲得了 “適度買入” 的平均推薦，Marketbeat Ratings 報告稱。一位投資分析師對該股票給予了賣出評級，一位給予了持有評級，三位給予了買入評級，還有一位給予了強烈買入評級。在過去一年中，發佈報告的經紀公司對該股票的平均一年目標價為 13.25 美元。</p>
<p>多家研究公司最近對 OBIO 進行了評論。巴克萊在 11 月 12 日的報告中將 Orchestra BioMed 的股票目標價從 12.00 美元下調至 11.00 美元，並對該股票給予了 “增持” 評級。Weiss Ratings 在 10 月 8 日的報告中重申了對 Orchestra BioMed 的 “賣出（e+）” 評級。HC Wainwright 在 9 月 4 日的報告中將 Orchestra BioMed 的目標價從 12.00 美元下調至 10.00 美元，並對該公司給予了 “買入” 評級。Chardan Capital 在 11 月 13 日的研究報告中重申了 “買入” 評級，並將 Orchestra BioMed 的目標價設定為 20.00 美元。最後，BTIG Research 在 8 月 20 日的研究報告中重申了對 Orchestra BioMed 的 “中性” 評級。</p>
<p>獲取 <strong>Orchestra BioMed</strong> 的提醒：</p>
<p><strong>查看我們關於 OBIO 的最新報告</strong></p>
<h2>對 Orchestra BioMed 的對沖基金看法</h2>
<p>多家對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Citadel Advisors LLC 在第三季度將其在 Orchestra BioMed 的持股增加了 9.2%。Citadel Advisors LLC 目前擁有 54,002 股該公司的股票，價值 134,000 美元，此前在上個季度又購買了 4,561 股。美國銀行在第二季度將其在 Orchestra BioMed 的持股增加了 35.7%。美國銀行目前擁有 21,577 股該公司的股票，價值 58,000 美元，此前在上個季度又購買了 5,678 股。德意志銀行在第一季度將其在 Orchestra BioMed 的持股增加了 67.3%。德意志銀行目前擁有 20,219 股該公司的股票，價值 87,000 美元，此前在上個季度又購買了 8,134 股。Catalyst Funds Management Pty Ltd 在第二季度購買了 Orchestra BioMed 的新頭寸，價值約 31,000 美元。最後，Creative Planning 在第二季度購買了 Orchestra BioMed 的新頭寸，價值約 40,000 美元。機構投資者和對沖基金持有該公司 53.20% 的股票。</p>
<h2>Orchestra BioMed 股票下跌 0.2%</h2>
<p>Orchestra BioMed 的股票在週二開盤時為 4.39 美元。該股票的 50 日移動平均價為 3.93 美元，200 日移動平均價為 3.23 美元。Orchestra BioMed 的 12 個月低點為 2.20 美元，12 個月高點為 6.30 美元。該股票的市值為 2.479 億美金，市盈率為-2.41，貝塔值為 0.62。該公司的流動比率為 4.73，速動比率為 4.72，債務與股本比率為 0.32。</p>
<p>Orchestra BioMed（納斯達克代碼：OBIO - 獲取免費報告）在 11 月 10 日公佈了其季度財報。該公司報告的每股收益（EPS）為-0.40 美元，低於市場共識預期的-0.38 美元，差距為-0.02 美元。Orchestra BioMed 的股本回報率為-320.09%，淨利潤率為-2,665.05%。該公司在本季度的收入為 86 萬美元，而分析師預期為 74 萬美元。整體來看，研究分析師預計 Orchestra BioMed 在本年度的每股收益將為-1.66 美元。</p>
<h2>Orchestra BioMed 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Orchestra BioMed Holdings, Inc.是一家生物醫學創新公司。該公司的旗艦產品候選包括用於治療高血壓（HTN）的 BackBeat 心臟神經調節療法（CNT）；以及用於治療動脈粥樣硬化性動脈疾病的 Virtue Sirolimus 血管灌注氣囊（SAB）。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Orchestra BioMed</li>
<li>股息貴族名單中的最佳：通過貴族指數積累財富</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的啓示</li>
<li>股票行業對成功投資的重要性</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>股票平均計算器</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次充滿活力</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Orchestra BioMed 嗎？</h2>
<p>在你考慮投資 Orchestra BioMed 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Orchestra BioMed 並不在名單上。</p>
<p>雖然 Orchestra BioMed 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OBIO

<p>Orchestra BioMed Holdings, Inc.（納斯達克代碼：OBIO）獲得了六位分析師的 “適度買入” 評級。該股票的平均一年目標價格為 13.25 美元。最近的分析師報告顯示評級不一，部分價格目標被下調。機構投資者已調整其持股比例，目前該股票的市值為 4.39 美元。公司報告了季度虧損，未能達到盈利預期，且股本回報率和淨利潤率均為負值。Orchestra BioMed 專注於生物醫學創新，包括高血壓和動脈疾病的治療</p>

<p>Shares of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) have been given an average recommendation of &#34;Moderate Buy&#34; by the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $13.25.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc.（納斯達克代碼：OBIO - 獲取免費報告）的股票在目前覆蓋該公司的六家評級機構中獲得了 “適度買入” 的平均推薦，Marketbeat Ratings 報告稱。一位投資分析師對該股票給予了賣出評級，一位給予了持有評級，三位給予了買入評級，還有一位給予了強烈買入評級。在過去一年中，發佈報告的經紀公司對該股票的平均一年目標價為 13.25 美元。</p>
</div><p>A number of research firms recently commented on OBIO. Barclays decreased their price objective on shares of Orchestra BioMed from $12.00 to $11.00 and set an &#34;overweight&#34; rating on the stock in a report on Wednesday, November 12th. Weiss Ratings restated a &#34;sell (e+)&#34; rating on shares of Orchestra BioMed in a report on Wednesday, October 8th. HC Wainwright reduced their price objective on Orchestra BioMed from $12.00 to $10.00 and set a &#34;buy&#34; rating for the company in a report on Thursday, September 4th. Chardan Capital reiterated a &#34;buy&#34; rating and set a $20.00 target price on shares of Orchestra BioMed in a research report on Thursday, November 13th. Finally, BTIG Research restated a &#34;neutral&#34; rating on shares of Orchestra BioMed in a research report on Wednesday, August 20th.</p>
<div class="lb-trans"><p>多家研究公司最近對 OBIO 進行了評論。巴克萊在 11 月 12 日的報告中將 Orchestra BioMed 的股票目標價從 12.00 美元下調至 11.00 美元，並對該股票給予了 “增持” 評級。Weiss Ratings 在 10 月 8 日的報告中重申了對 Orchestra BioMed 的 “賣出（e+）” 評級。HC Wainwright 在 9 月 4 日的報告中將 Orchestra BioMed 的目標價從 12.00 美元下調至 10.00 美元，並對該公司給予了 “買入” 評級。Chardan Capital 在 11 月 13 日的研究報告中重申了 “買入” 評級，並將 Orchestra BioMed 的目標價設定為 20.00 美元。最後，BTIG Research 在 8 月 20 日的研究報告中重申了對 Orchestra BioMed 的 “中性” 評級。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Orchestra BioMed</strong> 的提醒：</p>
</div><p><strong>View Our Latest Report on OBIO</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 OBIO 的最新報告</strong></p>
</div><h2>Hedge Funds Weigh In On Orchestra BioMed</h2>
<div class="lb-trans"><h2>對 Orchestra BioMed 的對沖基金看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC lifted its position in shares of Orchestra BioMed by 9.2% in the third quarter. Citadel Advisors LLC now owns 54,002 shares of the company's stock valued at $134,000 after acquiring an additional 4,561 shares in the last quarter. Bank of America Corp DE increased its position in Orchestra BioMed by 35.7% during the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company's stock worth $58,000 after purchasing an additional 5,678 shares in the last quarter. Deutsche Bank AG raised its stake in Orchestra BioMed by 67.3% in the 1st quarter. Deutsche Bank AG now owns 20,219 shares of the company's stock valued at $87,000 after purchasing an additional 8,134 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new position in Orchestra BioMed in the 2nd quarter valued at about $31,000. Finally, Creative Planning purchased a new position in Orchestra BioMed in the 2nd quarter valued at about $40,000. Institutional investors and hedge funds own 53.20% of the company's stock.</p>
<div class="lb-trans"><p>多家對沖基金和其他機構投資者最近增加或減少了對該公司的持股。Citadel Advisors LLC 在第三季度將其在 Orchestra BioMed 的持股增加了 9.2%。Citadel Advisors LLC 目前擁有 54,002 股該公司的股票，價值 134,000 美元，此前在上個季度又購買了 4,561 股。美國銀行在第二季度將其在 Orchestra BioMed 的持股增加了 35.7%。美國銀行目前擁有 21,577 股該公司的股票，價值 58,000 美元，此前在上個季度又購買了 5,678 股。德意志銀行在第一季度將其在 Orchestra BioMed 的持股增加了 67.3%。德意志銀行目前擁有 20,219 股該公司的股票，價值 87,000 美元，此前在上個季度又購買了 8,134 股。Catalyst Funds Management Pty Ltd 在第二季度購買了 Orchestra BioMed 的新頭寸，價值約 31,000 美元。最後，Creative Planning 在第二季度購買了 Orchestra BioMed 的新頭寸，價值約 40,000 美元。機構投資者和對沖基金持有該公司 53.20% 的股票。</p>
</div><h2>Orchestra BioMed Stock Down 0.2%</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票下跌 0.2%</h2>
</div><p>Orchestra BioMed stock opened at $4.39 on Tuesday. The stock has a 50 day moving average of $3.93 and a two-hundred day moving average of $3.23. Orchestra BioMed has a twelve month low of $2.20 and a twelve month high of $6.30. The stock has a market capitalization of $247.90 million, a price-to-earnings ratio of -2.41 and a beta of 0.62. The company has a current ratio of 4.73, a quick ratio of 4.72 and a debt-to-equity ratio of 0.32.</p>
<div class="lb-trans"><p>Orchestra BioMed 的股票在週二開盤時為 4.39 美元。該股票的 50 日移動平均價為 3.93 美元，200 日移動平均價為 3.23 美元。Orchestra BioMed 的 12 個月低點為 2.20 美元，12 個月高點為 6.30 美元。該股票的市值為 2.479 億美金，市盈率為-2.41，貝塔值為 0.62。該公司的流動比率為 4.73，速動比率為 4.72，債務與股本比率為 0.32。</p>
</div><p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Orchestra BioMed had a negative return on equity of 320.09% and a negative net margin of 2,665.05%.The firm had revenue of $0.86 million for the quarter, compared to analysts' expectations of $0.74 million. As a group, research analysts expect that Orchestra BioMed will post -1.66 earnings per share for the current year.</p>
<div class="lb-trans"><p>Orchestra BioMed（納斯達克代碼：OBIO - 獲取免費報告）在 11 月 10 日公佈了其季度財報。該公司報告的每股收益（EPS）為-0.40 美元，低於市場共識預期的-0.38 美元，差距為-0.02 美元。Orchestra BioMed 的股本回報率為-320.09%，淨利潤率為-2,665.05%。該公司在本季度的收入為 86 萬美元，而分析師預期為 74 萬美元。整體來看，研究分析師預計 Orchestra BioMed 在本年度的每股收益將為-1.66 美元。</p>
</div><h2>Orchestra BioMed Company Profile</h2>
<div class="lb-trans"><h2>Orchestra BioMed 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc.是一家生物醫學創新公司。該公司的旗艦產品候選包括用於治療高血壓（HTN）的 BackBeat 心臟神經調節療法（CNT）；以及用於治療動脈粥樣硬化性動脈疾病的 Virtue Sirolimus 血管灌注氣囊（SAB）。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>3 Stocks Most Likely to Split in 2026</li>
<li>Stock Average Calculator</li>
<li>ChargePoint's Comeback Story: Why This EV Stock Is Charging Up Again</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Orchestra BioMed</li>
<li>股息貴族名單中的最佳：通過貴族指數積累財富</li>
<li>Dollar Tree 的激增和 Home Depot 的下滑對消費者健康的啓示</li>
<li>股票行業對成功投資的重要性</li>
<li>2026 年最有可能拆分的三隻股票</li>
<li>股票平均計算器</li>
<li>ChargePoint 的復甦故事：為什麼這隻電動車股票再次充滿活力</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Orchestra BioMed 嗎？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Orchestra BioMed 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Orchestra BioMed 並不在名單上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Orchestra BioMed 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

分析師給予 Orchestra BioMed Holdings, Inc.（納斯達克股票代碼：OBIO）“適度買入” 的平均評級